Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised Controlled Crossover Trial of Inhaled Furosemide for Dyspnoea Relief in Advanced Heart Failure
2017-000124-95Phase 2Completed
- Sponsor
- University of Oxford
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of furosemide in chronic heart failure (CHF) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by University of Oxford. Primary endpoint: Air hunger VAS during experimentally induced breathlessness. Started May 2018; status: completed.
02
Drugs
furosemide
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2017-000124-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000124-95.